Iovance Biotherapeutics Q4 EPS $(0.45) Misses $(0.43) Estimate, Sales $482.00K
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics reported Q4 earnings with a loss of $0.45 per share, missing the consensus estimate of $0.43 per share. This represents a 29.69% improvement over the previous year's loss of $0.64 per share. The company also reported sales of $482,000 for the quarter.
February 28, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Iovance Biotherapeutics reported a Q4 loss of $0.45 per share, missing estimates and reported sales of $482,000.
Missing the EPS estimate could lead to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the improvement over last year's losses may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100